Baylor Selects Illumina Infinium® High-Density DNA Analysis Products Genomics Studies and puts Hospital Construction on Hold
Posted Mar 26 2009 3:53pm
Research and development with genomics is continuing at the Baylor School of Medicine; however, the construction of the new hospital has been put on hold to find additional capital through philanthropy, federal funds and other sources. BD
SAN DIEGO--( BUSINESS WIRE )--Illumina, Inc. (NASDAQ:ILMN) today announced that researchers at Baylor College of Medicine’s Medical Genetics Laboratories will use Illumina’s Infinium® High-Density (HD) DNA Analysis products to study genomic imprinting and its role in developmental diseases such as Prader-Willi syndrome (PWS), Angelman syndrome (AS), and other disorders caused by uniparental disomy. Baylor College of Medicine is committed to improving human health by providing the most current technologies for the medical genetics community. Illumina is showcasing the latest Information on its High-Density DNA Analysis products for cytogenetic research at the American College of Medical Genetics (ACMG) meeting this week in Tampa, Florida.
Arthur Beaudet, M.D., Professor and Chair of the Department of Molecular and Human Genetics at Baylor College of Medicine studies the role of epigenetic and de novo mutations in human disease. “We evaluated a variety of whole-genome arrays before opting to work with Illumina’s DNA Analysis products. Results from early tests show that we can quickly generate high-quality data using Illumina’s SNP arrays, providing us with the information required to more rapidly and accurately identify causative aberrations in the genome.”